



Prof. Dr. Anthony D. Ho

Ärztlicher Direktor der Medizinischen Klinik V.

Seine speziellen Forschungsgebiete sind die Stammzelltransplantation und die Behandlung von Leukämien und Lymphomen.

Tel.: 06221 - 56 8000/8001

Fax: 06221 - 56 5813

E-Mail: sekretariat.ho@med.uni-heidelberg.de



Medizinische Ausbildung

- 1968 - Studium der vorklinischen Medizin an der Universität Innsbruck, Österreich
- 1970 -
- 1970 - Studium der klinischen Medizin an der Universität Heidelberg
- 1974 -
- 1972 - Doktorarbeit bei Prof. Dr. Manfred Volm am Institut für Experimentelle Pathologie des Deutschen
- 1974 Krebsforschungszentrums, Heidelberg
- 1974 - Medizinalassistenten-Zeit am Universitäts-Klinikum der Universität Heidelberg (Kinderheilkunde,
- 1975 Innere Medizin und Chirurgie)
- 1975 - Weiterbildung in Innerer Medizin in der Abteilung für Innere Medizin V der Universität
- 1980 Heidelberg
- 1980 - Weiterbildung in Hämatologie-Onkologie bei Herrn Prof. Dr. Werner Hunstein, Abteilung für
- 1982 Innere Medizin V der Universität Heidelberg

[Nach oben](#)

Qualifikationen

- 1974 Staatsexamen an der Fakultät für Klinische Medizin der Universität Heidelberg
- 1974 Promotion mit der Note *magna cum laude* an der Fakultät für Theoretische Medizin
- 1975 Approbation als Arzt
- 1980 Anerkennung als Arzt für Innere Medizin durch die Bezirksärztekammer Nordbaden
- 1982 Habilitation an der Fakultät für Klinische Medizin I der Universität Heidelberg
- 1983 Anerkennung der Teilgebietsbezeichnung *Hämatologie* durch die Bezirksärztekammer Nordbaden
- 1984 Ermächtigung zur Weiterbildung in Teilgebiet für Hämatologie, Ärztekammer Nordbaden
- 1985 Berufung als Fachgutachter in den Weiterbildungsausschuß für das Teilgebiet Hämatologie durch den Vorstand der Bezirksärztekammer Nordbaden



- 1989 Ernennung als außerplanmäßiger Professor durch das Ministerium für Wissenschaft und Kunst, Baden -Württemberg
- 1990 Licentiate Examination of the Medical Council of Canada (LMCC)
- 1990 Specialist Certification in Internal Medicine and Fellowship, Royal College of Physicians and Surgeons of Canada
- 1994 Licence Examination, Medical Board of California, U. S. A.
- Nach oben

Beruflicher Werdegang

Deutschland

- 1978 - 1988 Leiter der Hämatologisch-Onkologischen Ambulanz der Abteilung für Innere Medizin V, Universität Heidelberg
- 1979 - 1983 Venia legendi, Universität Heidelberg
- 1979 - 1988 Leiter der Hämatologischen Diagnostik, Abteilung für Innere Medizin V, Universität Heidelberg
- 1983 - 1988 Oberarzt der Abteilung für Innere Medizin V, Universität Heidelberg
- 1983 - 1989 Privat-Dozent der Universität Heidelberg
- 1988 - 1990 Leitender Oberarzt an der Abteilung für Innere Medizin V, Universität Heidelberg
- 1989 - 1992 Außerplanmäßiger Professor der Medizin, Universität Heidelberg
- seit
6.3.1998 C4 Professor und Ärztlicher Direktor der Abteilung Innere Medizin V, Universität Heidelberg

England (United Kingdom)

- 1982 - 1983 Honorary Lecturer, Department of Hematology, Royal Free Hospital and School of Medicine, Hampstead, London (als Stipendiat der Deutschen Krebshilfe, Mildred-Scheel-Stiftung)

Kanada

- 1990 -
1992 Professor, Department of Medicine, Faculty of Medicine, University of Ottawa
- 1990 -
1992 Director of Research and Head of Clinical Trials, Northeastern Ontario Regional Cancer Center, Sudbury, Ontario
- 1991 -
1992 Adjunct Professor, Department of Chemistry, Laurentian University, Sudbury, Ontario
- Adjunct Professor, Faculty of Medicine, University of Ottawa



1992 -
1993

United States of America

- 1992 - 1998 Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, University of California, San Diego, California
- 1992 - 1998 Director of Bone Marrow Transplantation and Malignant Hematology Program, UCSD Cancer Center, University of California, San Diego, California

[Nach oben](#)

Mitgliedschaft in Fachkommissionen

- 1986 - Member, Leukemia Study Group, European Organization for Research and Treatment of Cancer
1992 (EORTC), Brussels
- 1990 - Member, Leukemia and Lymphoma Committee, National Cancer Institute of Canada (NCIC)
1992
- 1990 - Member, Research Ethics Board, Laurentian Hospital, Sudbury, Ontario, Canada
1992
- 1991 - Member, Provincial Committee on Cytogenetics and Molecular Genetics, Ontario Cancer
1992 Foundation, Toronto, Canada
- 1991 - Member, Provincial Research Advisory Panel
1992
- 1991 - Chair, Treatment Guidelines Sub-Committee on Leukemia and Lymphoma, Provincial Advisory
1992 Committee on Professional Programs, Ontario Cancer Foundation, Toronto, Canada
- 1992 - Chair, Bone Marrow/Stem Cell Transplantation Steering Committee, University of California, San
1998 Diego Medical Center, San Diego, California
- 1992 - Chair, Organizing Committee, International Symposium: Recent Advances in Hematopoietic Stem
Cell Transplantation - Clinical Progress, New Technologies and Gene Therapy, sponsored by the
University of California, San Diego and the International Society for Hematotherapy and Graft
Engineering
- 1993 - Member, Transplantation Services Committee, University of California, San Diego Medical Center
1998



1993 - Member, Molecular Diagnostics Committee, Department of Medicine, University of California, San Diego

1995 - Consultant, Division of Grant Reviews, National Institute of Health, Bethesda, MD
1998

1997 - Board Member, Stern Foundation, San Diego

Nach oben

Mitgliedschaft in folgenden akademischen Gesellschaften

1980 - Deutsche Gesellschaft für Hämatologie

1981 - Deutsche Krebsgesellschaft

1985 - 1990 European Organization for Research and Treatment of Cancer, Leukemia Co-operative Group

1986 - American Society of Hematology

1987 - American Society of Clinical Oncology

1987 - Honorary member of "Centre Oncologique et Biologique de Recherche Appliquée", Paris, France

1988 - International Society of Hematology

1989 - European Society for Medical Oncology

1990 - American Association of Cancer Research

1992 - International Society of Hematotherapy and Graft Engineering

1993 - American Society for Blood and Marrow Transplantation

1993 - International Society of Experimental Hematology

1994 - American Medical Association

Nach oben

Publikationen

Auszug der Research & Invited Articles, Monographs and Editorials ab dem Jahr 2000 (Stand: Februar 2007):

- Voso MT, Pantel G, Weis M, Schmidt P, Martin S, Moos M, **Ho AD**, Haas R, Hohaus S. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 109:729-735,



2000

- Nierhoff D, Horvath HC, Mytilineos J, Golling M, Bud O, Klar E, Opelz G, Voso MT, **Ho AD**, Haas R, Hohaus S. Microchimerism in bone-marrow-derived CD34+ cells of patients after liver transplantation. *Blood* 96:763-767, 2000
- Fiehn C, Wettschureck N, Krauthoff A, Haas R, **Ho AD**. Bone marrow-derived cells as carriers of recombinant immunomodulatory cytokine genes to lymphoid organs. *Cancer Gene Ther* 7:1105-1112, 2000
- Schneeweiss A, Hensel M, Goerner R, Khbeis T, Hohaus S, Egerer G, Solomayer E, Haas R, Grischke EM, Bastert G, **Ho AD**. Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancer. *Stem Cells* 19:151-160, 2001
- Hensel M, Breitbart A, **Ho AD**. Autologous hematopoietic stem-cell transplantation for Behcet's disease with pulmonary involvement. *N Engl J Med* 344: 69, 2001
- Möhler TM, Neben K, Benner A, Egerer G, Krasniqi F, **Ho AD**, Goldschmidt H. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. *Blood* 8:3846-3848, 2001
- Harter C, Salwender HJ, Bach A, Egerer G, Goldschmidt, **Ho AD**. Catheter-related infection and thrombosis of the internal jugular vein in hematologic-oncologic patients undergoing chemotherapy: a prospective comparison of silver-coated and uncoated catheters. *Cancer* 94:245-251, 2002
- Hensel M, Schneeweiss A, Sinn HP, Egerer G, Kornacker M, Solomayer E, Haas R, Bastert G, **Ho AD**. Stem cell dose and tumorbiologic parameters as prognostic markers for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous blood stem cell support. *Stem Cells* 20:32-40, 2002
- Hensel M, Egerer G, Schneeweiss A, Goldschmidt H, **Ho AD**. Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation. *Ann Oncology* 13:209-217, 2002
- Frühauf S, Srbic K, Seggewiss R, Topaly J, **Ho AD**. Functional characterization of podia formation in normal and malignant hematopoietic cells. *J Leukoc Biol.* 71:425-32, 2002
- Punzel M, Zhang T, Liu D, Eckstein V, **Ho AD**. Functional analysis of initial cell divisions defines the subsequent fate of individual human CD34+CD38- cells. *Experimental Hematology* 30:464-472, 2002
- Hensel M, Schneeweiss A, Sinn HP, Egerer G, Solomayer E, Haas R, Bastert G, **Ho AD**. P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support. *Int J Cancer* 100:290-296, 2002
- Krämer A, Neben K, **Ho AD**. Centrosome replication, genomic instability and cancer. *Leukemia* 16:767-775, 2002
- Abdallah A, Egerer G, Weber-Nordt RM, Körbling M, Haas R, **Ho AD**. Long-term outcome in acute myelogenous leukemia autografted with mafosfamide-purged marrow in a single institution: adverse events and incidence of secondary myelodysplasia. *Bone Marrow Transplantation* 30:15-22, 2002
- Schneeweiss A, Hensel M, Sinn P, Khbeis T, Haas R, Bastert G, **Ho AD**. Characteristics associated with long-term progression-free survival following high-dose chemotherapy in metastatic breast cancer and influence of chemotherapy dose. *Ann Oncol.* 13:679-688, 2002



- Görner M, Kordelas I, Thalheimer M, Luft T, Pfeiffer S, Ustaoglu F, Punzel M, Weber-Nordt R, Moos M, Goldschmidt H, **Ho AD**. Stable mixed chimerism after T cell-depleted allogeneic hematopoietic stem cell transplantation using conditioning with low-dose total body irradiation and fludarabine. *Bone Marrow Transplant*. 29:621-624, 2002
- Krämer A, Schultheis B, Bergmann J, Willer A, Hegenbart U, **Ho AD**, Goldschmidt H, Hehlmann R. Alterations of the cyclin D1/pRb/p16INK4A pathway in multiple myeloma. *Leukemia* 16:1844-1851, 2002
- Viardot A, Möller P, Högel J, Werner K, Mechttersheimer G, **Ho AD**, Ott G, Barth TFE, Siebert R, Gesk S, Schlegelberger B, Döhner H, Bentz M. Clinicopathologic correlations of genomic gains and losses in follicular lymphoma. *J Clin Oncology* 20:4523-4530, 2002
- Neben K, Giesecke C, Schweizer S, **Ho AD**, Kramer A. Centrosome aberrations in acute myeloid leukemia are correlated with cytogenetic risk profile. *Blood* 101:289-291, 2003
- Neben K, Mytilineos J, Moehler TM, Preiss A, Kraemer A, **Ho AD**, Opelz G, Goldschmidt H. Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. *Blood* 100:2263-2265, 2002
- Egerer G, Goldschmidt H, Zoz M, **Ho AD**. Autologous bone marrow transplantation in adult patients with acute lymphoblastic leukemia. *Leukemia & Lymphoma* 44:9-14, 2003
- Laufs S, Gentner B, Nagy KZ, Jauch A, Benner A, Naundorf S, Kuehlcke K, Schiedlmeier B, **Ho AD**, Zeller WJ, Fruehauf S. Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells. *Blood* 101:2191-2198, 2003
- Punzel M, Liu D, Zhang T, Eckstein V, Miesala K, **Ho AD**. The symmetry of initial divisions of human hematopoietic progenitors is altered only by the cellular microenvironment. *Exp Hematol* 31:339-347, 2003
- **Ho AD**, Punzel M. Hematopoietic stem cells: can old cells learn new tricks? *J Leukocyte Biology* 73:547-555, 2003
- Seggewiss R, Buss EC, Herrmann D, Goldschmidt H, **Ho AD**, Frühauf S. Kinetics of peripheral blood stem cell mobilization following G-CSF-supported chemotherapy. *Stem Cells* 21:568-574, 2003
- Schneeweiss A, Sinn HP, Ehemann V, Khbeis T, Neben K, Krause U, **Ho AD**, Bastert G, Krämer K. Centrosomal aberrations in primary invasive breast cancer are associated with nodal status and hormone receptor expression. *Int J Cancer* 107:346-352, 2003
- Luft T, Moos M, Goldschmidt H, **Ho AD**, Görner M. Dissociation of putative graft-versus-haematopoiesis and graft-versus-myeloma effects in patients with rapidly progressive multiple myeloma. *Brit J Haematol* 123:646-653, 2003
- Frühauf S, Topaly J, Schad M, Paschka P, Gschaidmeier H, Zeller WJ, Hochhaus A, **Ho AD**. Imatinib restores expression of CD62L in BCR-ABL-positive cells. *J Leukoc Biol*. 73:600-603, 2003
- Hensel M, Kornacker M, Yammeni S, Egerer G, **Ho AD**. Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia. *Brit J Haematol*. 122:600-606, 2003
- Krämer A, Schweizer S, Neben K, Giesecke C, Kalla J, Katzenberger T, Benner A, Müller-Hermelink HK, **Ho AD**, Ott G. Centrosome aberrations as a possible mechanism for chromosomal instability in non-Hodgkin's lymphoma. *Leukemia* 17:2207-2213, 2003



- Neben K, Tews B, Wrobel G, Hahn M, Kokocinski F, Giesecke C, Krause U, **Ho AD**, Kramer A, Lichter P. Gene expression patterns in acute myeloid leukemia correlate with centrosome aberrations and numerical chromosome changes. *Oncogene* 23:2379-2384, 2004
- Kasper B, Lehnert T, Bernd L, Mechttersheimer G, Goldschmidt H, **Ho AD**, Egerer G. Autografting for sarcoma ? High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas. *Bone Marrow Transplantation* 34: 37-41, 2004
- Wagner W, Ansorge A, Wirkner U, Eckstein V, Schwager C, Blake J, Miesala K, Selig J, Saffrich R, Ansorge W, **Ho AD**. Molecular evidence for stem cell function of the slow-dividing fraction among human hematopoietic progenitor cells by genome-wide analysis. *Blood* 104:675-686, 2004
- Luft T, Marakovsky E, Schnurr M, Knebel K, Kirsch M, Görner M, Skoda R, **Ho AD**, Nawroth P, Bierhaus A. Tuning the volume of the immune response: strength and persistence of stimulation determine migration and cytokine secretion of dendritic cells. *Blood* 104:1066-1074, 2004
- Lowe B, Willand L, Eich W, Zipfel S, **Ho AD**, Herzog W, Fiehn C. Psychiatric comorbidity and work disability in patients with inflammatory rheumatic diseases. *Psychosom Med.* 66:395-402, 2004
- Möhler TM, Hillengass J, Goldschmidt H, **Ho AD**. Antiangiogenic therapy in hematologic malignancies. *Curr Pharm Des.* 10:1221-1234, 2004
- Leo E, Scheuer L, Schmidt-Wolf IGH, Kerowgan M, Schmitt C, Leo A, Tanja B, Kraemer A, Mey U, Benner A, Parwaresch R, **Ho AD**. Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma. *Eur J Haematol* 73:251-257, 2004
- Schneeweiss A, Diel I, Hensel M, Kaul S, Sinn HP, Unnebrink K, Rudlowski C, Lauschner I, Schuetz F, Egerer G, Haas R, **Ho AD**, Bastert G. Micrometastatic bone marrow cells at diagnosis have no impact on survival of primary breast cancer patients with extensive axillary lymph node involvement treated with stem cell-supported high-dose chemotherapy. *Ann Oncol* 15:1627-1632, 2004
- Perz JB, Schönland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M, Linke RP, **Ho AD**, High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. *Brit J Haematol* 127:543-551, 2004
- Reusch U, Le Gall F, Hensel M, Moldenhauer G, **Ho AD**, Little M, Kipriyanov SM. Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells. *Int J Cancer* 112:509-518, 2004
- Mei S, **Ho AD**, Mahlknecht U. Role of histone deacetylase inhibitors in the treatment of cancer. *Int J Oncol.* 25:1509-1519, 2004
- Niemeyer P, Krause U, Fellenberg J, Kasten P, Seckinger A, **Ho AD**, Simank HG. Evaluation of mineralized collagen and alpha-tricalcium phosphate as scaffolds for tissue engineering of bone using human mesenchymal stem cells. *Cells Tissues Organs* 177:68-78, 2004
- **Ho AD**. Kinetics and symmetry of divisions of hematopoietic stem cells. *Exp Hematol* 33:1-8, 2005
- Munder M, Mollinedo F, Calafat J, Canchado J, Gil-Lamaignere C, Fuentes JM, Luckner C, Doschko G, Soler G, Eichmann K, Müller FM, **Ho AD**, Goerner M, Modolell M. Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity. *Blood* 105:2549-2556, 2005
- Choi C, Witzens M, Bueur M, Feuerer M, Sommerfeldt N, Trojan A, **Ho AD**, Schirmacher V, Goldschmidt H, Beckhove P. Enrichment of functional CD8 memory T cells specific for MUC1 in



- bone marrow of patients with multiple myeloma. *Blood* 105:2132-2134, 2005
- Kornacker M, Luft T, **Ho AD**, Schaefer HJ. Thrombotic microangiopathy after combined autografting-allografting for multiple myeloma - report of three cases. *Eur J Haematol.* 74:250-253, 2005
 - Frühauf S, Buss EC, Topaly J, Kreipe HH, **Ho AD**. Myeloablative conditioning in myelofibrosis using i.v. treosulfan and autologous peripheral blood progenitor cell transplantation with high doses of CD34+ cells results in hematologic responses - follow-up of three patients. *Haematologica* 90:ECR08, 2005
 - Raab MS, Cremer FW, Breitkreutz IN, Gerull S, Luft T, Benner A, Goerner M, **Ho AD**, Goldschmidt H, Moos M. Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myeloma. *Ann Oncol.* 16:611-617, 2005
 - Nikendei C, Schilling T, Nawroth P, Hensel M, **Ho AD**, Schwenger V, Zeier M, Herzog W, Schellberg D, Katus HA, Dengler T, Stremmel W, Müller M, Jünger J. Integrated skills laboratory concept for undergraduate training in internal medicine. *Dtsch Med Wochenschr.* 130: 1133-1138, 2005
 - Kasper B, **Ho AD**, Egerer G. Is there an indication for high-dose chemotherapy in the treatment of bone and soft-tissue sarcoma? *Oncology* 68:115-121, 2005
 - Krämer A, Neben K, **Ho AD**. Centrosome aberrations in hematological malignancies. *Cell Biol Int.* 29:375-383, 2005
 - **Ho AD**, Wagner W, Mahlkecht U. Stem cells and ageing. *EMBO Rep.* 2005 Jul;6 Suppl 1:S35-38
 - Bochtler T, Hensel M, Lorenz HM, HoAD, Mahlkecht U. Chronic lymphocytic leukaemia and concomitant relapsing polychondritis: a report on one treatment for the combined manifestation of two diseases. *Rheumatology (Oxford)* 44:1199, 2005
 - Wagner W, Laufs S, Blake J, Schwager C, Wu X, Zeller JW, **Ho AD**, Frühauf S. Retroviral integration sites correlate with expressed genes in hematopoietic stem cells. *Stem Cells* 23:1050-1058, 2005
 - Wagner W, Saffrich R, Wirkner U, Eckstein V, Blake J, Ansorge A, Schwager C, Wein F, Miesala K, Ansorge W, **Ho AD**. Hematopoietic progenitor cells and cellular microenvironment - Behavioral and molecular changes upon interaction. *Stem Cells* 23:1180-1191, 2005
 - Hensel M, Villalobos M, Kornacker M, Krasniqi F, **Ho AD**. Pentostatin/cyclophosphamide with or without Rituximab: An effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. *Clin Lymphoma Myeloma* 6:131-135, 2005

Auszug der Research & Invited Articles, Monographs and Editorials (1997 - 1999)



- Moskowitz CH, Stiff P, Gordon MS, McNiece I, **Ho AD**, Costa JJ, Broun ER, Bayer RA, Wyres M, Hill J, Jelaca-Maxwell K, Nichols CR, Brown SL, Nimer SD, and Gabilove J: Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients--results of a phase I/II trial. *Blood* 89(9):3136-3147, 1997
- Gervaix A, Schwarz L, Law P, **Ho AD**, Looney D, Lane T, Wong-Staal F. Gene therapy targeting peripheral blood CD34+ hematopoietic stem cells of HIV-infected individuals. *Human Gene Therapy* 8:2229-2238, 1997
- Glück S, Ross AA, Layton TJ, Ostrander AB, Goldstein LC, Porter K, **Ho AD**: Decrease in tumor cell contamination and progenitor cell yield in leukapheresis products after consecutive cycles of chemotherapy for breast cancer treatment. *Biology of Blood and Marrow Transplantation* 3:316-323, 1997
- Li X, Gervaix A, Kang D, Law P, Spector SA, **Ho AD**, Wong-Staal F: Gene therapy targeting cord blood-derived CD34+ cells from HIV-exposed infants: preclinical studies. *Gene Therapy* 5:233-239, 1998
- Sinclair AM, Agrawal YP, Elbar E, Agrawal R, **Ho AD** and Levine F: Interaction of vesicular stomatitis virus-G pseudotyped retrovirus with CD34+ and CD34+CD38- hematopoietic progenitor cells. *Gene Therapy* 4:918-927, 1997
- Huang S, Law P, Young D, **Ho AD**: Candidate hematopoietic stem cells from fetal tissues, umbilical cord blood versus adult bone marrow and mobilized peripheral blood. *Exp Hematol* 26:1162-1171, 1998
- Bashey A, Shephard S, Frankel W, Wang-Rodriguez J, Cahill T, Chamberlain M, Mason JR, **Ho AD**, Corringham RE. Induction of molecular remission by donor peripheral blood leukocyte therapy in patients relapsing with extramedullary blastic phase chronic myeloid leukemia after allogeneic bone marrow transplantation. *Onkology Reports*. 5:281-285, 1998
- Poeschla E, Gilbert J, Li Xinqiang, Huang S, **Ho AD**, Wong-Staal, F: Identification of a human immunodeficiency virus type 2 (HIV-2) encapsidation determinant and transduction of nondividing human cells by HIV-2-based lentivirus vectors. *J Virol* 72(8):6527-6536, 1998
- McLaughlin P, Grillo-Lopez J, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, **Ho AD**, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. *J Clin Oncology* 16(8):2825-2833, 1998
- **Ho AD**, Huang S, Law P: Hematopoietic progenitor cells derived from fetal tissues, umbilical cord blood, adult bone marrow and mobilized peripheral blood. *Cancer Research Therapy and Control*, 7:49-56, 1998.
- Lane TA, **Ho AD**, Bashey A, Peterson S, Young D, Mason JR and Law P: Mobilization of blood-derived stem and progenitor cells in normal subjects by granulocyte-macrophage- and granulocyte-colony-stimulating factors. *Transfusion* 39:39-47, 1999
- Law P, Lane TA, Gervaix A, Looney D, Schwarz L, Young D, Ramos S, Wong-Staal F, Recktenwald D, **Ho AD**: Mobilization of peripheral blood progenitor cells from human immunodeficiency virus-infected individuals. *Exp Hematol* 27:147-154, 1999
- Kasper B, Fruehauf S, Schiedlmeier B, Buchdunger E, **Ho AD**, Zeller WJ: Favorable therapeutic index of a p210BCR-ABL-specific tyrosine kinase inhibitor; activity on lineage-committed and



primitive chronic myelogenous leukemia progenitors. *Cancer Chemother Pharmacol* 44: 433-438, 1999

- Huang S, Law P, Francis K, Palsson BO, **Ho AD** : Symmetry of initial cell divisions among primitive hematopoietic progenitors is independent of ontogenic age and regulatory molecules. *Blood* 94:2595-2604, 1999
- Huang S, Chen Z, Yu JF, Young D, Bashey A, **Ho AD** : Correlation between IL-3 receptor expression and growth potential of human CD34+ hematopoietic cells from different tissues. *Stem Cells* 17: 265-272, 1999

Eine vollständige Liste aller Veröffentlichungen finden Sie bei [Pubmed](#).

[Nach oben](#)